期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 56, 期 36, 页码 10845-10849出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201701366
关键词
arsenic trioxide; chronic myeloid leukemia; folate receptor-beta; human serum albumin; smart nanodrugs
资金
- NSFC [21521063, 21327009, 21405041, 61527806]
- Science and Technology Project of Hunan Province [2015RS4019]
- China Postdoctoral Science Foundation [2016T90751, 2015M570679, 2013T60828]
- US National Institutes of Health [GM079359]
Arsenic trioxide (ATO, As2O3) is currently used to treat acute promyelocytic leukemia. However, expanding its use to include high-dose treatment of other cancers is severely hampered by serious side effects on healthy organs. To address these limitations, we loaded ATO onto folate (FA)-labeled human serum albumin (HSA) pretreated with glutathione (GSH) based on the low pH- and GSH-sensitive arsenic-sulfur bond, and we termed the resulting smart nanodrug as FA-HSA-ATO. FA-HSA-ATO could specifically recognize folate receptor-beta-positive (FR beta+) chronic myeloid leukemia (CML) cells, resulting in more intracellular accumulation of ATO. Furthermore, the nanodrug could upregulate FR beta expression in CML cancer cells and xenograft tumor model, facilitating even more recruitment and uptake of FR beta-targeting drugs. In vitro and in vivo experiments indicate that the nanodrug significantly alleviates side effects and improves therapeutic efficacy of ATO on CML and xenograft tumor model.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据